{"id":300178,"date":"2026-02-16T01:25:18","date_gmt":"2026-02-16T01:25:18","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/300178\/"},"modified":"2026-02-16T01:25:18","modified_gmt":"2026-02-16T01:25:18","slug":"time100-health-victor-bulto-time","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/300178\/","title":{"rendered":"TIME100 Health: Victor Bult\u00f3 | TIME"},"content":{"rendered":"<p class=\"rich-text mb-6 self-baseline font-graphik text-body-large text-black-coffee focus-visible:outline focus-visible:outline-black-coffee focus-visible:outline-2 focus-visible:outline-offset-2 focus-visible:shadow-focus-color text-left\" data-testid=\"paragraph-content\">Cancer treatments are moving toward more precision-based strategies that target just cancer cells and leave healthy ones alone. Radiation therapy, however, has been slow to fully optimize this approach since it\u2019s challenging to target radioactive material without harming nearby tissue. But Victor Bult\u00f3, president of Novartis U.S., and his team have been leading the way with the first approved radioligand therapies, which link radioactive material with markers designed to find and bind just to tumor cells. The therapy allows doctors to treat even difficult-to-find cancers that have spread.\u00a0<\/p>\n<p class=\"rich-text self-baseline font-graphik text-body-large text-black-coffee mb-0 focus-visible:outline focus-visible:outline-black-coffee focus-visible:outline-2 focus-visible:outline-offset-2 focus-visible:shadow-focus-color text-left\" data-testid=\"paragraph-content\">The approved treatments target prostate cancer and neuroendocrine tumors, but Bult\u00f3 says the company is studying the therapy for other cancers as well. In 2026, Novartis announced plans to build its fourth U.S. manufacturing site for radioligand therapies. \u201cWe believe this will become a mainstream technology to fight cancer,\u201d Bult\u00f3 says.<\/p>\n","protected":false},"excerpt":{"rendered":"Cancer treatments are moving toward more precision-based strategies that target just cancer cells and leave healthy ones alone.&hellip;\n","protected":false},"author":2,"featured_media":300179,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[47092,9810,103,397,396,61,60,28976,709,47094,12277,139977],"class_list":{"0":"post-300178","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-accolades","9":"tag-franchise","10":"tag-health","11":"tag-health-care","12":"tag-healthcare","13":"tag-ie","14":"tag-ireland","15":"tag-list","16":"tag-magazine","17":"tag-special-project","18":"tag-sponsorshipblock","19":"tag-time100-health-2026"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/300178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=300178"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/300178\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/300179"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=300178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=300178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=300178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}